13F Holdings
中文EN

VCEL Vericel Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 887359 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY25.3%
TTM net income YoY154.6%
TTM EPS YoY146.2%
Revenue 3-yr CAGR20.5%
Net income 3-yr CAGR—

Margins

Gross margin74.5%
Operating margin8.3%
Net margin10.3%
FCF margin17.9%
EBITDA margin12.4%

Returns

ROE9.4%
ROA6.9%
ROIC (approx.)9.0%
Asset turnover0.67x

Leverage & solvency

Liabilities / assets25.7%
Debt / equity0.00x
Current ratio5.13x
Interest coverage42.01x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$276.26M$237.22M$197.52M$164.37M$156.18M
Cost of revenue$70.66M$65.12M$61.94M$54.58M$50.16M
Gross profit$205.60M$172.11M$135.58M$109.79M$106.03M
R&D expense$27.56M$24.80M$21.04M$19.94M$16.29M
SG&A expense$166.99M$142.79M$121.00M$106.90M$97.59M
Operating income$11.04M$4.52M-$6.46M-$17.06M-$7.85M
Interest expense$630,000$614,000$600,000$366,000$4,000
Pretax income$17.38M$10.51M-$2.37M-$15.99M-$7.58M
Income tax$859,000$148,000$814,000$721,000-$111,000
Net income$16.52M$10.36M-$3.18M-$16.71M-$7.47M
EBITDA$22.59M$10.02M-$1.83M-$13.08M-$4.89M
EPS (basic)0.330.21-0.07-0.35-0.16
EPS (diluted)0.320.20-0.07-0.35-0.16
Weighted avg. shares (diluted)52.15M51.68M47.59M47.13M46.47M
Balance sheet
Cash & equivalents$100.09M$85.05M$69.09M$51.07M$68.54M
Short-term investments$37.41M$41.69M$40.47M$68.47M$35.07M
Receivables$84.63M$61.38M$58.36M$46.54M$37.44M
Inventory$17.56M$17.37M$13.09M$15.99M$13.38M
Current assets$247.44M$212.78M$205.63M$186.87M$158.46M
PP&E, net$108.40M$103.16M$41.63M$15.84M$13.31M
Intangibles$5.62M$6.25M$6.88M$7.50M$0
Total assets$487.97M$432.72M$353.66M$273.00M$243.71M
Current liabilities$49.15M$50.29M$45.75M$37.46M$26.05M
Total liabilities$133.33M$140.75M$127.70M$80.73M$73.24M
Shareholders' equity$354.64M$291.97M$225.95M$192.27M$170.46M
Shares outstanding50.62M49.63M47.83M47.25M46.88M
Cash flow statement
Operating cash flow$51.91M$58.16M$35.31M$17.69M$29.04M
Capital expenditure$27.16M$63.97M$20.01M$7.60M$7.92M
Free cash flow$24.75M-$5.81M$15.30M$10.09M$21.12M
Investing cash flow-$43.94M-$79.03M-$3.13M-$36.21M-$3.50M
Financing cash flow$7.07M$19.05M$3.62M$1.04M$9.17M
Depreciation & amortization$11.54M$5.50M$4.63M$3.98M$2.96M
Stock-based compensation$38.77M$36.49M$32.33M$37.18M$34.32M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.